Q5109 — Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
Q5109 is a HCPCS Level II code for injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg. It belongs to the Temporary Codes section. It was terminated on December 31, 2025 and is not valid on new claims.
This code has been terminated
CMS terminated Q5109 on December 31, 2025. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q5109
- Long descriptor
- Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Short descriptor
- Injection, ixifi, 10 mg
- Added
- January 1, 2019
- Terminated
- December 31, 2025
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to Q5109
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q5109 is not quite right, the correct code is very often within a few positions of it.
- Q5101Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5102Injection, infliximab, biosimilar, 10 mgterminated
- Q5103Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5110Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
- Q5112Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg
- Q5113Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
- Q5114Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
- Q5115Injection, rituximab-abbs, biosimilar, (truxima), 10 mg
- Q5116Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg
- Q5117Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
Questions about Q5109
What is HCPCS code Q5109?
Q5109 is a HCPCS Level II code for injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg. It sits in the Temporary Codes section.
Does Medicare cover Q5109?
The CMS HCPCS file marks Q5109 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is Q5109 still valid?
No. Q5109 was terminated on December 31, 2025 and should not be used on new claims.